Click Holdings Limited (NASDAQ:CLIK) Short Interest Update

Click Holdings Limited (NASDAQ:CLIK) was the target of a significant decrease in short interest in June. As of June 30th, there was short interest totaling 37,691 shares, a decrease of 38.2% from the June 15th total of 60,989 shares. Approximately 3.3% of the company’s stock are short sold. Based on an average trading volume of 123,258 shares, the short-interest ratio is currently 0.3 days.

Hedge Funds Weigh In On Click

A hedge fund recently bought a new position in Click stock. Renaissance Technologies LLC bought a new stake in Click Holdings Limited (NASDAQ:CLIK) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned approximately 1.23% of Click as of its most recent SEC filing.

Click Price Performance

NASDAQ CLIK opened at $1.53 on Friday. The business has a fifty day simple moving average of $1.59 and a 200 day simple moving average of $2.83. Click has a 12 month low of $1.32 and a 12 month high of $14.40.

Click (NASDAQ:CLIK) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.10 earnings per share (EPS) for the quarter. The firm had revenue of $3.79 million for the quarter.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CLIK. Weiss Ratings restated a “sell (d)” rating on shares of Click in a report on Wednesday, June 24th. Wall Street Zen upgraded Click to a “hold” rating in a report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

About Click

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.